{"groups":[{"description":"Participants received sacituzumab govitecan 10 mg/kg of body weight, administered as a slow intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, occurrence of unacceptable adverse events (AEs), or another treatment discontinuation criterion was met (up to 40.1 months).","id":"FG000","title":"Sacituzumab Govitecan"},{"description":"Participants received TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent treatment that was determined by the investigator before participant randomization until progression of disease, occurrence of unacceptable adverse events (AEs), or another treatment discontinuation criterion was met. Dosing per National Comprehensive Cancer Network (NCCN) guidelines (with dose modifications for if toxic)\n\n* Eribulin was administered IV at a dose 1.4 mg/m\\^2 at North American sites and 1.2 mg/m\\^2 at European sites on Days 1 and 8 of a 21-day cycle (up to 22.5 months).\n* Capecitabine 1000 to 1250 mg/m\\^2 was administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period (up to 12.9 months).\n* Gemcitabine 800 to 1200 mg/m\\^2 was administered IV on Days 1, 8, and 15 of a 28-day cycle (up to 22.3 months).\n* Vinorelbine 25 mg/m\\^2 was administered as a weekly IV injection (up to 8.1 months). Vinorelbine was not allowed as TPC for any participant with Grade 2 neuropathy.","id":"FG001","title":"Treatment of Physician's Choice (TPC)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"220"},{"groupId":"FG001","numSubjects":"192"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"40"}],"type":"Informed consent withdrawn"},{"reasons":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"23"}],"type":"Sponsor request"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"}],"type":"Reason not specified"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Covid19"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"272"},{"groupId":"FG001","numSubjects":"271"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"268"},{"groupId":"FG001","numSubjects":"249"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"272"},{"groupId":"FG001","numSubjects":"271"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"776 participants were screened.","recruitmentDetails":"Participants were enrolled at study sites in Belgium, Canada, France, Germany, Italy, the Netherlands, Spain, the United Kingdom, and the United States."}